About: CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial
Creator	Anand, Anjana Brown, Janet Brown, Sarah Coleman, Rob Flanagan, Louise Howell, Sacha Kendall, Jessica Macpherson, Iain Palmieri, Carlo Rathbone, Emma Reid, Amber Twelves, Chris
Source	PMC
abstract	BACKGROUND: A substantial proportion of breast cancer patients develop metastatic disease, with over 450,000 deaths globally per year. Bone is the most common first site of metastatic disease accounting for 40% of all first recurrence and 70% of patients with advanced disease develop skeletal involvement. Treatment of bone metastases currently focusses on symptom relief and prevention and treatment of skeletal complications. However, there remains a need for further treatment options for patients with bone metastases. Combining systemic therapy with a bone-targeted agent, such as radium-223, may provide an effective treatment with minimal additional side effects. METHODS/DESIGN: CARBON is a UK-based, open-label, multi-centre study which comprises an initial safety phase to establish the feasibility and safety of combining radium-223 given on a 6-weekly schedule in combination with orally administered capecitabine followed by a randomised extension phase to further characterise the safety profile and provide preliminary estimation of efficacy. DISCUSSION: The CARBON study is important as the results will be the first to assess radium-223 with chemotherapy in advanced breast cancer. If the results find acceptable rates of toxicity with a decrease in bone turnover markers, further work will be necessary in a phase II/III setting to assess the efficacy and clinical benefit. TRIAL REGISTRATION: ISRCTN, ISRCTN92755158, Registered on 17 February 2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3643-6) contains supplementary material, which is available to authorized users.
has issue date	2020-01-15(xsd:dateTime)
bibo:doi	10.1186/s13063-019-3643-6
bibo:pmid	31941523
has license	cc-by
sha1sum (hex)	71f4295cec1e88caa3b0efa23eda0b0ba6d7c1a6
schema:url	https://doi.org/10.1186/s13063-019-3643-6
resource representing a document's title	CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial
has PubMed Central identifier	PMC6961242
has PubMed identifier	31941523
schema:publication	Trials
resource representing a document's body	covid:71f4295cec1e88caa3b0efa23eda0b0ba6d7c1a6#body_text
is schema:about of	named entity 'develop' named entity 'substantial' named entity 'accounting' named entity 'extension' named entity 'provide' named entity 'safety' named entity 'randomised controlled trial' named entity 'RADIUM-223' named entity 'SITE OF' named entity 'METASTATIC DISEASE' named entity 'skeletal' named entity 'estimation' named entity 'orally administered' named entity 'radium' named entity 'common' named entity 'bone metastases' named entity 'Background' named entity 'weekly' named entity 'options' named entity 'combination' named entity 'bone metastases' named entity 'CARBON' named entity 'breast cancer' named entity 'radium-223' named entity 'CARBON' named entity 'BONe metastases' named entity 'breast cancer' named entity 'spinal cord compression' named entity 'bladder' named entity 'endocrine' named entity 'radium-223' named entity 'Bone Metastases' named entity 'safety profile' named entity 'SAEs' named entity 'radium-223' named entity 'metastasis' named entity 'kidneys' named entity 'paclitaxel' named entity 'radium-223' named entity 'phase II' named entity 'CARBON' named entity 'PSA' named entity 'Radium-223' named entity 'voided urine' named entity 'NYHA' named entity 'capecitabine' named entity 'breast cancer' named entity 'Gastrointestinal' named entity 'Clinical Trials' named entity 'morbidity' named entity 'DLTs' named entity 'hormone-refractory prostate cancer' named entity 'radionuclide' named entity 'warfarin' named entity 'myelotoxicity' named entity 'bone scintigraphy' named entity 'hypercalcaemia' named entity 'hazard ratio' named entity 'Kaplan-Meier method' named entity 'blood transfusion' named entity 'sample size' named entity 'quality-of-life' named entity 'carcinoma in situ' named entity 'bone metastases' named entity 'radium-223' named entity 'myelodysplasia' named entity 'malabsorption' named entity 'hormone-refractory prostate cancer' named entity 'bone metastases' named entity 'radium-223'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software